Rigel Historical Cash Flow
| RIGL Stock | USD 27.61 0.27 0.97% |
Analysis of Rigel Pharmaceuticals cash flow over time is an excellent tool to project Rigel Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 15.8 M or Total Cash From Financing Activities of 17.4 M as it is a great indicator of Rigel Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Rigel Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rigel Pharmaceuticals is a good buy for the upcoming year.
Rigel |
About Rigel Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Rigel balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Rigel's non-liquid assets can be easily converted into cash.
Rigel Pharmaceuticals Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Rigel Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Rigel Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from Rigel Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Rigel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.At this time, Rigel Pharmaceuticals' Change To Inventory is quite stable compared to the past year. Change To Account Receivables is expected to rise to about 10.3 M this year, although the value of Other Cashflows From Financing Activities is projected to rise to (1.5 M).
Rigel Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Rigel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rigel Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (53.8M) | 7.9M | (11.5M) | 5.6M | 8.3M | 8.7M | |
| Free Cash Flow | (43.0M) | (53.4M) | 5.3M | (74.2M) | (20.7M) | (21.8M) | |
| Change In Working Capital | 16.7M | (30.3M) | 9.7M | (29.0M) | 9.5M | 10.0M | |
| Begin Period Cash Flow | 76.3M | 22.5M | 30.4M | 18.9M | 24.5M | 31.7M | |
| Other Cashflows From Financing Activities | 19.6M | 2.6M | 62.7M | 2.1M | (1.6M) | (1.5M) | |
| Depreciation | 683K | 706K | 1.2M | 998K | 1.2M | 1.7M | |
| Other Non Cash Items | (1.1M) | (122K) | 3.1M | 481K | (213K) | (223.7K) | |
| Capital Expenditures | 1.5M | 1.3M | 627K | 450K | 15M | 15.8M | |
| Total Cash From Operating Activities | (41.5M) | (52.2M) | 5.9M | (73.8M) | (5.7M) | (6.0M) | |
| Net Income | (66.9M) | (29.7M) | (17.9M) | (58.6M) | (25.1M) | (26.3M) | |
| Total Cash From Financing Activities | 11.4M | 12.6M | 62.7M | 6.6M | 18.4M | 17.4M | |
| End Period Cash Flow | 22.5M | 30.4M | 18.9M | 24.5M | 32.8M | 32.8M | |
| Change To Inventory | (366K) | (126K) | (4.9M) | (2.4M) | 1.2M | 1.2M | |
| Stock Based Compensation | 9.1M | 7.3M | 9.5M | 12.4M | 8.8M | 8.7M | |
| Change To Account Receivables | (6.0M) | (5.9M) | 501K | (24.8M) | 9.8M | 10.3M | |
| Change To Liabilities | (1.1M) | 3.4M | (381K) | (3.5M) | (3.2M) | (3.0M) | |
| Total Cashflows From Investing Activities | (23.7M) | 47.5M | (80.0M) | 72.8M | 83.7M | 87.9M | |
| Sale Purchase Of Stock | 1.6M | 2.6M | 4.8M | 2.1M | 1.9M | 1.8M | |
| Investments | (22.2M) | 48.7M | (79.4M) | 72.3M | 21.2M | 13.4M | |
| Cash And Cash Equivalents Changes | (53.8M) | 7.9M | (11.5M) | 5.6M | 5.0M | 5.3M | |
| Cash Flows Other Operating | 24.1M | (27.8M) | 5.6M | 1.6M | 1.8M | 1.9M | |
| Other Cashflows From Investing Activities | 732K | 26.1M | (22.2M) | 893K | 803.7K | 470.1K | |
| Change To Netincome | 9.1M | 7.3M | 12.9M | 13.1M | 11.8M | 7.6M | |
| Change Receivables | (6.0M) | (5.9M) | 501K | (24.8M) | (22.4M) | (21.2M) | |
| Change To Operating Activities | 1.0M | (374K) | 14.5M | (4.4M) | (5.0M) | (4.8M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.